MAP2K7 Antibodies

Dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7)

Dual specificity protein kinase which functions as an essential part of the MAP kinase signal transduction pathway. Essential part of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway.

With MAP2K4/MKK4, is the one of the only known kinase to directly trigger the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both trigger the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif.

Gene Information

Human
Gene Name:	MAP2K7
Uniprot:	O14733
Entrez:	5609

Family

Belongs to:
protein kinase superfamily

Alternative Names

c-Jun N-terminal kinase kinase 2; dual specificity mitogen-activated protein kinase kinase 7; EC 2.7.12.2; JNK kinase 2; JNK-activating kinase 2; JNKK 2; JNKK2; MAP kinase kinase 7; MAP2K7; MAPK/ERK kinase 7; MAPKK7; MEK 7; MEK7; mitogen-activated protein kinase kinase 7; MKE7; MKK7; MKK7MAPKK 7; PRKMK7

Molecular Weight

Mass (kDA):
47.485 kDA

Genomic Context

Human
Location:	19p13.2
Sequence:	19; NC_000019.10 (7903785..7914478)

Tissue Specificity

Ubiquitous; with highest level of expression in skeletal muscle. Isoform 3 is found at low levels in placenta, fetal liver, and skeletal muscle.

Subcellular Localizations

Nucleus. Cytoplasm.

Diseases

• Malignant Neoplasms
• Neoplasms
• Carcinoma
• Hypertrophy
• Inflammation
• Cardiac Hypertrophy
• Cell Transformation, Neoplastic
• Physiological Stress
• Leukemia
• Rheumatoid Arthritis
• Arthritis
• Prostatic Neoplasms

• Malignant Neoplasm Of Prostate
• Heart Failure
• Adenocarcinoma
• Liver Carcinoma
• Metaplastic Cell Transformation
• Genotoxic Stress
• Degenerative Polyarthritis

Interacting Proteins

• GADD45B
• LRRK2
• MAP3K7
• MAPK8
• MAPK8IP1

Pathways

• Cell Death
• Cell Cycle
• Cell Proliferation
• Cell Cycle Arrest
• Localization
• Cell Growth
• Pathogenesis
• Signal Transmission
• Rna Interference
• Cell Migration
• Cell Differentiation
• Oncogenesis
• Response To Stress

• Programmed Cell Death
• Aging
• Senescence
• Cytokine Production
• Viral Replication
• Secretion
• Cell Activation

PTMs

• Phosphorylation
• Cleavage

• Dephosphorylation
• Ribosylation

• Ubiquitination

Research Areas

• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MAP2K7

Best Uses Of The MAP2K7 Marker

This article will discuss the different uses of the MAP2K7 Cell-Based ELISA Kit and how to store it. This information will be applicable for scientists all over the world. The best use for this marker is in the field of biology, where it is used in the detection of microbial pathogens. Boster Bio also offers product credits for scientists' work.

MAP2K7 Cell-Based ELISA Kit

The MAP2K7 Cell-Based ELIISA Kit is a convenient, high-throughput test that can monitor the MAP2K7 protein expression profile in cells. The kit measures relative amounts of MAP2K7 in cultured cells, and is also ideal for screening the effects of various treatments and activators. You can perform these assays in a variety of settings, including the in vitro setting, in a single experiment, or across a range of cultures.

The MAP2K7 antibody is highly specific and can detect protein levels in a variety of biological samples. Its high sensitivity is enhanced to a picogram level. It has been validated against a range of samples. Validation images and procedures are available on request. Its Supervision secondary antibody saves more than 30 minutes of IHC analysis and is based on an insight into immunogen design. It is supported by technical support from BeNeLux distributor Sanbio.

Storage of MAP2K7 Marker

MAP2K7 is an important protein that is activated by heat, ultraviolet irradiation, anisomycin, and tumor necrosis factor-alpha. MAP2K7 is involved in various physiological pathways, including regulating the activity of genes and regulating the immune system. MAP2K7 is highly expressed in the nervous system, where it is used to stimulate the production of new neurons.

Studies have shown that impaired MAP2K7 expression may contribute to the development of schizophrenia and other neurological conditions. In mice lacking the gene, MAP2K7 levels decreased and their behaviour was remarkably similar to wild-type controls. Moreover, mice lacking the Map2K7 gene showed decreased correct responses, increased perseverance, and were embryonically lethal. These results suggest that MAP2K7 may also be involved in the development of the PFC-relevant cognitive features of schizophrenia.

The LRRC8E and MAP2K7 markers have been linked to schizophrenia, but the association between the two genes is not clear yet. Currently, this gene has been associated with schizophrenia only after GWAS analyses. This association is not yet confirmed by existing SNP databases, but our own results suggest that it is not causal. LRRC8E is located 2 kb upstream of MAP2K7.

Activated MAP2K7 responds to changes in its environment by increasing its activity. As a result, MAP2K7 protein levels increase in some tissues, including the kidney. Moreover, the MAP2K7 gene is involved in the regulation of actin, as well as neurodevelopment. MAP2K7 also responds to an increase in ATP levels. Thus, the MAP2K7 gene is a critical factor in a variety of medical disorders.

The rs4804833 polymorphism, located upstream of alternatively spliced exon b, is highly conserved in other species. Furthermore, the short intronic region containing the rs4804833 polymorphism shows enhanced expression of the MAP2K7 g isoform in homozygotes with the rs3679 risk genotype.

The MAP2K7 gene has been associated with schizophrenia by genetic evidence. This gene is involved in signalling between neurons and the immune system. It is activated by stress stimuli such as hypoxia and undernutrition. Moreover, there are antenatal and perinatal risk factors for schizophrenia associated with low MAP2K7 expression. These results demonstrate that MAP2K7 gene represents a confluence of genetic and environmental factors that may play a role in the development of schizophrenia.

Applications of MAP2K7 Marker

In cancer, MAP2K7 expression is a key determinant of stem cell-like properties. In addition, MAP2K7 splicing can indicate response to JNK inhibition. This biomarker can identify cancer cells that are particularly sensitive to JNK inhibition. Further, it may be useful in the development of targeted therapies for various types of cancer. This research highlights the potential of MAP2K7 as a biomarker for cancer therapy.

The antileukemic activity of 5Z7O was confirmed in a panel of T-ALL and LCL cells. Treatment of T-ALL cells with 5Z7O significantly reduced MAP2K7 activity, inhibited cell proliferation, and inhibited the G2/M checkpoint. Moreover, the inhibitors induced apoptosis and reduced the survival of leukemic cells, demonstrating the ability to affect tumor cells with MAP2K7 inhibition. In addition, 5Z7O also induced synergistic effects with dexamethasone.

MAP2K7 is not widely expressed in normal tissues, however, the physiological functions of this enzyme are important to understand its possible toxicities. The mapping of MAP2K7 activity in normal tissues is limited by the embryonic deletion of the Map2K7 gene, which results in lethality. However, heterozygous mapping of the Map2k7 gene in humans overcame lethality and the defects associated with hepatocyte organization. MAP2K7-/ hepatoblasts displayed decreased levels of cdc2, a protein involved in the cell cycle.

The pharmacological inhibition of MAP2K7 is an emerging therapeutic target for cancer. Small molecules targeting MAP2K7 may have therapeutic value. Besides targeting tumors, small molecules may also have therapeutic benefits in treating other diseases. These small molecules are currently being studied in several clinical trials, and more research is necessary to validate their potential. This research will provide new insights into the molecular basis for future therapies.

MAP2K7 is a gene in the MAP kinase family. It is important to note that it plays a role in stress-induced JNK activation in mast cells. In addition, it inhibits the proliferation of immune cells through antigen or growth factor-driven signaling. Although MAP2K7 is an important marker in cancer research, there are currently no clinical trials demonstrating its use.

Recent studies have shown that elevated CXCL10 levels in the embryonic brain of Map2k7 haploinsufficient mice can lead to a phenotypic disorder. Although this increased CXCL10 level is unlikely to cause any neurological damage, it may disrupt the delicate balance that occurs during neurodevelopment. In addition, Map2k7-hh mice exhibit differential regulation of immune molecules including IL-2 and IL-12. IL-6 is both anti-inflammatory and pro-inflammatory, so it is important to understand how Map2k7 Hz mice respond to different stimuli.

Imaging Mass Cytometry can detect MAP2K7 by using antibodies to other proteins in the body. In this case, 5Z7O, an inhibitor of JNK, inhibits activated MAP2K7. It also inhibits downstream JNK. These studies support the potential use of MAP2K7 in cancer research. If you're interested in the potential of MAP2K7 as a biomarker, we strongly encourage you to get started.